Thoracoscopic lobectomy of lung
Conditions
Interventions
Group 2:0.5% ropivacaine 20ml + 2 ml dexamethasone paravertebral block
Group 1:0.5% ropivacaine 20ml + 2 ml NS paravertebral block
Sponsors
Affiliated Hospital of Xuzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. aged 18~75 years; 2. ASAI~III; 3. Elective thoracoscopic lobectomy; 4. Willing to cooperate with the trial.
Exclusion criteria
Exclusion criteria: 1. Contraindications for glucocorticoid use such as diabetes mellitus, adrenal hyperfunction, fungal infection, etc.; 2. Allergy to any of the drugs used in this study, such as local anesthetics, glucocorticoids, etc.; 3. Patients with severe cardiovascular and cerebrovascular diseases, respiratory diseases and abnormal liver and kidney function before operation; 4. Severe spinal or thoracic malformation; 5. Puncture site skin damage with infection; 6. coagulation disorders; 7. morbid obesit (BMI>35 kg/m2); 8. Chronic pain history, long-term painkiller therapy; 9. Hearing impairment or speech impairment, unable to complete the VAS score.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Analgesic duration of TPVB(Defined as the time between the end of the injection and the first addition of painkillers to the patient after surgery); | — |
Countries
China
Contacts
Public ContactHuang Chenchen
Affiliated Hospital of Xuzhou Medical University
Outcome results
None listed